Last reviewed · How we verify

NCT03032081

High Intensity Interval Training in Heart Failure

Withdrawn NA Last updated 23 August 2017
What this trial tests

NA trial testing High intensity exercise in Heart Failure. Withdrawn.

Timeline
2 March 2017
Primary endpoint
1 July 2018
1 July 2018

Quick facts

Lead sponsorGeorgia State University
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Start date2 March 2017
Primary completion1 July 2018
Estimated completion1 July 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Georgia State University

Who can join

Adults 40 to 65, any sex, with Heart Failure or Physical Activity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will assess the efficacy and safety of utilizing high-intensity interval training in stable heart failure patients on functional outcomes. Specifically, an assessment of baseline peak oxygen uptake and peak cardiac output will be assessed before and 8 weeks after intense interval training. Measurements of quality of life will be assessed before and after training as well as the number of arrhythmic events before and after training. The control group will be a group that will follow a moderate exercise training protocol over a similar period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of High intensity exercise

Trials testing the same drug.

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Georgia State University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03032081.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing